Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAPN2-MSN
- Development stage
- Preclinical
- Lead developer
- Vrije University Medical Center
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**CAPN2-MSN** is a preclinical, calpain-2-responsive mesoporous silica nanoparticle delivery system developed for targeted treatment of pancreatic ductal adenocarcinoma. The nanoparticle is loaded with **paclitaxel** and sealed using a CAPN2-cleavable protease-responsive molecular gate; after cellular uptake by pancreatic cancer cells, intracellular calpain-2 cleaves the gate and releases paclitaxel. In pancreatic cancer cell models and two mouse models, paclitaxel-loaded CAPN2-MSN reduced tumor growth at least as effectively as free paclitaxel while reducing leukopenia and limiting toxicity to healthy cells and organs. ([scholarlypublications.universiteitleiden.nl](https://scholarlypublications.universiteitleiden.nl/access/item%3A3970609/view))
- Other names
- CAPN2-MSNCAPN-2-MSNCAPN 2-MSNCAPN2-MSNsCAPN-2-MSNsCAPN 2-MSNsCAPN2-responsive mesoporous silica nanoparticlesCAPN-2-responsive mesoporous silica nanoparticlesCAPN 2-responsive mesoporous silica nanoparticles
02
Targets
CAPN (Schistosoma calpain large subunit family)
Beyond the preview
Go deeper on CAPN2-MSN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAPN2-MSN.